Home › Therapeutic areas › Agents for liver disease
Japan market screening · Therapeutic class
肝臓疾患用剤 · Japan Standard Commodity Classification
6 molecules in this class are marketed in Japan across 7 products. 0 of those products are not shipping normally today — 0.0% of the class. Supply status is reported to the Ministry of Health, Labour and Welfare and updated daily.
Ordered by how many products compete. Constrained means limited supply or supply suspended; supply suspended does not mean discontinued.
| Molecule | Products | Companies | Constrained | Supply mix |
|---|---|---|---|---|
| Odevixibat Hydrateオデビキシバット水和物 | 2 | 1 | — | |
| Defibrotide Sodiumデフィブロチドナトリウム | 1 | 1 | — | |
| Maralixibat Chlorideマラリキシバット塩化物 | 1 | 1 | — | |
| Propagermaniumプロパゲルマニウム | 1 | 1 | — | |
| Taurineタウリン | 1 | 1 | — | |
| Tioproninチオプロニン | 1 | 1 | — |
Products counts every marketed product across all strengths and forms, not companies. Companies is the number of companies marketing that molecule; the same company may appear under several molecules, so the column does not add up to a class total. Market size sits on each molecule's own page, valued at national price rather than transaction price. Figures are as at 2026-08-28.
Tell us which molecules matter to you. We will tell you what the public data can and cannot answer before you commission anything.
Send an enquiryOur Database Division replies in English within three business days (Japan time).